Senseonics (NYSE:SENS) Sets New 52-Week High – Time to Buy?

Senseonics Holdings, Inc. (NYSE:SENS) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $0.85 and last traded at $0.84, with a volume of 16359777 shares traded. The stock had previously closed at $0.71.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SENS. StockNews.com began coverage on Senseonics in a report on Thursday, December 26th. They issued a “sell” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $2.00 price target on shares of Senseonics in a report on Friday, November 15th.

Senseonics Stock Down 3.1 %

The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. The firm has a market cap of $504.78 million, a PE ratio of -6.52 and a beta of 0.64. The business has a fifty day moving average price of $0.43 and a two-hundred day moving average price of $0.40.

Insider Buying and Selling at Senseonics

In other news, CEO Timothy T. Goodnow bought 315,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were purchased at an average price of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the purchase, the chief executive officer now directly owns 11,310,355 shares of the company’s stock, valued at $3,506,210.05. This trade represents a 2.86 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Frederick T. Sullivan purchased 124,933 shares of Senseonics stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $0.38 per share, with a total value of $47,474.54. Following the transaction, the chief financial officer now directly owns 2,478,844 shares of the company’s stock, valued at approximately $941,960.72. The trade was a 5.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Institutional Trading of Senseonics

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC lifted its position in shares of Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after buying an additional 167,970 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Senseonics in the third quarter worth about $117,000. Cubist Systematic Strategies LLC lifted its position in shares of Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares during the last quarter. Symmetry Partners LLC acquired a new position in shares of Senseonics during the 3rd quarter worth about $164,000. Finally, Geode Capital Management LLC lifted its position in shares of Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock worth $2,042,000 after purchasing an additional 179,103 shares during the last quarter. Institutional investors and hedge funds own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.